REGN
NASDAQRegeneron Pharmaceuticals Inc.
Price$833.92-2.79 (-0.33%)
01:30 PM07:45 PM
News · 26 weeks61+33%
2026-03-012026-08-23
Mix1890d
- Other7(39%)
- Insider5(28%)
- SEC Filings4(22%)
- Earnings1(6%)
- Leadership1(6%)
Latest news
25 items- INSIDEREVP General Counsel and Secret Larosa Joseph J exercised 12,282 shares at a strike of $381.92 and covered exercise/tax liability with 9,019 shares, increasing direct ownership by 10% to 36,373 units (SEC Form 4)4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
- SECSEC Form N-PX filed by Regeneron Pharmaceuticals Inc.N-PX - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
- INSIDEREVP Finance CFO Fenimore Christopher R. exercised 6,283 shares at a strike of $381.92 and covered exercise/tax liability with 4,599 shares, increasing direct ownership by 9% to 19,984 units (SEC Form 4)4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
- PRRegeneron Announces Investor Conference PresentationsTARRYTOWN, N.Y., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: 2026 Wells Fargo Healthcare Conference at 8:45 a.m. ET on Wednesday, September 9, 2026Morgan Stanley 24th Annual Global Healthcare Conference at 1:05 p.m. ET on Monday, September 14, 2026Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum at 10:30 a.m. ET on Wednesday, September 23, 2026 The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be archived on the Company's website
- PRPasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)FOP is an ultra-rare genetic disorder characterized by rogue bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability Approval based on results from the OPTIMA trial demonstrating a 90% or greater reduction in new HO lesions at 56 weeks with a dramatic reduction in clinician-assessed flare-ups in adults with FOP TARRYTOWN, N.Y., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the U.S. Food and Drug Administration (FDA) has granted approval for Pasatru™ (garetosmab-grts) to reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in ad
- INSIDERDirector Guarini Kathryn exercised 400 shares at a strike of $719.37 and sold $320,000 worth of shares (400 units at $800.00) as part of a pre-agreed trading plan (SEC Form 4)4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
- INSIDERDirector Zoghbi Huda Y exercised 800 shares at a strike of $376.69 and sold $640,000 worth of shares (800 units at $800.00) as part of a pre-agreed trading plan (SEC Form 4)4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
- SECSEC Form 13F-HR filed by Regeneron Pharmaceuticals Inc.13F-HR - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
- PRRegeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative InnovationEarly-career scientists from New York University, Stanford University and Rensselaer Polytechnic Institute were recognized for their ambitious "dream project" proposals TARRYTOWN, N.Y., July 31, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the recipients of the 2026 Regeneron Prize for Creative Innovation ("the Regeneron Prize"). This annual award celebrates outstanding early-career scientists, nominated by their research universities, whose creativity and innovation set new standards in biomedical research. Winners are chosen by a panel of Regeneron scientists based on the scientific merit, originality and creativity of 'dream project' proposals
- SECSEC Form 10-Q filed by Regeneron Pharmaceuticals Inc.10-Q - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
- SECRegeneron Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
- PRTessera Therapeutics Appoints Joseph Romanelli as President and Chief Executive OfficerVeteran pharmaceutical executive to lead Tessera's next phase of growth as the company advances Gene Writing from platform innovation toward a broad clinical pipeline of genetic medicinesSOMERVILLE, Mass., July 23, 2026 /PRNewswire/ -- Tessera Therapeutics ("Tessera"), the biotechnology company pioneering a new approach to genetic medicine known as Gene Writing™, today announced the appointment of Joseph Romanelli as President and Chief Executive Officer. Romanelli succeeds Michael Severino who has led the company since June 2022. Romanelli will join Tessera's board of directors and also join Tessera's founder, Flagship Pioneering, as a CEO-Partner.
- INSIDERDirector Ryan Arthur F sold $130,030 worth of shares (200 units at $650.15) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 17,303 units (SEC Form 4)4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
- SECRegeneron Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
- PRRegeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and WebcastTARRYTOWN, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2026 financial and operating results on Thursday, July 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailin
- PRCemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)Cemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosing FDA accepted NDA under Priority Review with a target action date in November 2026; European Commission decision anticipated in the second half of 2027 TARRYTOWN, N.Y., June 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted the regulatory applications for cemdisiran to treat adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. The FDA will
- SECRegeneron Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
- PRRegeneron's Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus OutbreakInmazeb® (a three-antibody cocktail consisting of maftivimab, atoltivimab and odesivimab-ebgn) was the first Ebola treatment approved by the U.S. Food and Drug Administration, indicated specifically for the Orthoebolavirus zairense species, and has been administered to hundreds of patients Maftivimab, the most potent neutralizing antibody in Inmazeb, has shown broad activity in vitro against multiple Ebola species, including Bundibugyo Maftivimab has been recommended to be studied as a monotherapy in the current outbreak TARRYTOWN, N.Y., May 28, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that maftivimab, the most potent neutralizing antibody
- PROtarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing LossTARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated Assessment the Marketing Authorization Application (MAA) for Otarmeni™ (lunsotogene parvec), an in vivo adeno-associated virus vector-based gene therapy for the treatment of biallelic OTOF variant-associated hearing loss. Otarmeni, formerly known as DB-OTO, previously received Orphan Designation from the EMA. If approved, Otarmeni will be the first gene therapy for OTOF-related hearing loss in the European Union (EU). The MAA is supported by data from the pivotal CHORD clinical trial, in which 24 parti
- PRREGN SHAREHOLDER INVESTIGATION: SueWallSt Investigates Regeneron Pharmaceuticals for Possible Securities Law ViolationsRegeneron executives pointed to optimistic outcomes for a study that was revealed to have failed to achieve its primary endpoint only two months later; shares dropped sharply when the results came in.NEW YORK, May 19, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ:REGN) shareholders saw the stock decline more than 10% when the market opened on May 18, 2026 after investors digested the weekend news that Regeneron's Phase 3 melanoma trial of Fianlimab + Libtayo failed to meet its primary endpoint versus Merck's Keytruda (pembrolizumab). Those who lost money on REGN are encouraged to submit their information to SueWallSt. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueW
- ANALYSTRegeneron Pharma downgraded by Citigroup with a new price targetCitigroup downgraded Regeneron Pharma from Buy to Neutral and set a new price target of $700.00
- ANALYSTRegeneron Pharma downgraded by Leerink Partners with a new price targetLeerink Partners downgraded Regeneron Pharma from Outperform to Market Perform and set a new price target of $641.00
- PRRegeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic AreasThe multi-target collaboration combines Regeneron's industry-leading antibody capabilities with Parabilis' novel Helicon™ peptide platform Agreement provides for Parabilis to receive $125M from Regeneron, consisting of a $50M upfront payment and $75M equity commitment, with up to approximately $2.2B in additional potential milestone payments plus tiered royalties TARRYTOWN, N.Y., May 18, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a strategic research collaboration with Parabilis Medicines to discover and develop multiple therapeutic candidates based on Parabilis' Helicon™ peptide platform, with a particular focus on Antibody-Helicon™ Conjugat
- PRUPDATE – Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering FairTARRYTOWN, N.Y. and WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc., and Society for Science (the Society) announced that Hikaru Kuribayashi, 17, of Sapporo, Japan won the $100,000 George D. Yancopoulos Innovator Award at the Regeneron International Science and Engineering Fair 2026 (Regeneron ISEF), the world's largest precollege science and engineering competition. For more information about the top winners and access to visual assets visit our media kit here. Key Takeaways: This year's finalists received more than $7 million in awards based on their projects' creativity, innovation, and depth of scientific inquiry.The top winners were honored at the Pho
- PRNext Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering FairHikaru Kuribayashi, 17, receives $100,000 Top Award for his creation of a simulation program to understand complex folding at the world's largest pre-college STEM competition. TARRYTOWN, N.Y. and WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Society for Science (the Society) announced that Hikaru Kuribayashi, 17, of Sapporo, Japan won the $100,000 George D. Yancopoulos Innovator Award at the Regeneron International Science and Engineering Fair 2026 (Regeneron ISEF), the world's largest precollege science and engineering competition. Key Takeaways: This year's finalists received more than $7 million in awards based on their projects' creat
REGN FAQ
8 questionsWhat does Regeneron Pharmaceuticals Inc. do?
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults...Where does REGN stock trade?
Regeneron Pharmaceuticals Inc. (REGN) is listed on NASDAQ.What sector and industry is REGN in?
Regeneron Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Regeneron Pharmaceuticals Inc. go public?
Regeneron Pharmaceuticals Inc. (REGN) completed its IPO in 1991.Does REGN pay a dividend?
REGN's most recent ex-dividend date was 2026-08-18 with a cash dividend of $0.94 per share. No future ex-date is on file yet.What are analysts saying about REGN?
Regeneron Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Citigroup: Neutral on 2026-05-18.What companies are similar to REGN?
Notable peers in the same industry include ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), SNY (Sanofi). Compare REGN side-by-side with any of them on Quantisnow.How can I track REGN on Quantisnow?
Quantisnow aggregates Regeneron Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow REGN to receive live email and push alerts on every new disclosure.